Literature DB >> 30903708

Treatment with either COX-2 inhibitor or 5-LOX inhibitor causes no compensation between COX-2 pathway and 5-LOX pathway in chronic aluminum overload-induced liver injury in rats.

Hui Xia1, Qin He2, Hong Wang1, Yongming Wang3, Yang Yang1, Yuke Li1, Jiahua Zhang1, Zhihao Chen1, Junqing Yang1.   

Abstract

This study was designed to observe the compensation between cyclooxygenase-2 pathway and 5-lipoxygenase pathway in chronic aluminum overload-induced liver injury rats. A rat hepatic injury model of chronic aluminum injury was established by the intragastric administration of aluminum gluconate (Al3 + 200 mg/kg per day, 5 days a week for 20 weeks). The COX-2 inhibitor [meloxicam (1 mg/kg)] and 5-LOX inhibitor [caffeic acid (30 mg/kg)] were intragastrically administered 1 h after aluminum administration. The histopathology was detected by hematoxylin-eosin staining. A series of biochemical indicators were measured with biochemistry assay or ELISAs. The expressions of COX-2 and 5-LOX were measured by immunohistochemistry. Our experimental results showed that aluminum overload caused a significant damage to the liver and also significantly increased the expressions of COX-2, 5-LOX and the levels of inflammation and oxidative stress. The administration of meloxicam and caffeic acid significantly protected livers against histopathological injury, significantly decreased plasma ALT, AST, and ALP levels, significantly decreased TNF-α, IL-6, IL-1β levels, and oxidative stress. However, the administration of caffeic acid did not significantly increase the expression of COX-2 compared with the model group. On the other hand, the administration of meloxicam also did not significantly increase the expression of 5-LOX compared with the model group. Our results indicate that there is no compensation between COX-2 pathway and 5-LOX pathway by inhibiting either COX-2 or 5-LOX in chronic aluminum overload-induced liver injury rat.
© 2019 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  5-lipoxygenase; aluminum; compensation; cyclooxygenase-2; liver injury

Mesh:

Substances:

Year:  2019        PMID: 30903708     DOI: 10.1111/fcp.12465

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  3 in total

1.  The hepatoprotective efficacy and biological mechanisms of three phenylethanoid glycosides from cistanches herba and their metabolites based on intestinal bacteria and network pharmacology.

Authors:  Yongli Guo; Qingling Cui; Shumeng Ren; Deguo Hao; Toshio Morikawa; Dongmei Wang; Xiaoqiu Liu; Yingni Pan
Journal:  J Nat Med       Date:  2021-05-18       Impact factor: 2.343

2.  Metabolomic Profiling Reveals Protective Effects and Mechanisms of Sea Buckthorn Sterol against Carbon Tetrachloride-Induced Acute Liver Injury in Rats.

Authors:  Changting Sheng; Yang Guo; Jing Ma; Eun-Kyung Hong; Benyin Zhang; Yongjing Yang; Xiaofeng Zhang; Dejun Zhang
Journal:  Molecules       Date:  2022-03-29       Impact factor: 4.411

3.  A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies.

Authors:  Cezary Pawlukianiec; Małgorzata Ewa Gryciuk; Kacper Maksymilian Mil; Małgorzata Żendzian-Piotrowska; Anna Zalewska; Mateusz Maciejczyk
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.